Diag-Nose.io — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Diag-Nose.io is a private, clinical-stage biotech company pioneering AI-driven precision diagnostics for chronic respiratory diseases. Founded in 2020 by a Stanford-based team, the company has developed the RhinoMAP platform, which uses nasal liquid biopsies to generate proteomic biomarker profiles, aiming to predict treatment response and guide therapy. The company is pre-revenue, having closed an oversubscribed $3.15M seed round in early 2025, and is actively recruiting patients for its clinical studies to validate its platform. Its long-term vision is to both improve patient outcomes through precise diagnostics and discover novel therapeutic targets.

AsthmaChronic SinusitisCOPD

Technology Platform

RhinoMAP platform: integrates nasal microsampling (ABEL Microsampler®), proteomic analysis, and AI/machine learning algorithms to decode airway biology from nasal lining fluid for precision diagnostics and therapy guidance.

Opportunities

The massive and growing global burden of chronic respiratory disease represents a multi-billion dollar market with a severe lack of precision diagnostic tools.

Success would enable a high-value diagnostic business and create a proprietary data asset that could be leveraged for therapeutic discovery partnerships or internal drug development programs.

Risk Factors

The core scientific premise that nasal biomarkers can predict treatment response for lung diseases requires extensive clinical validation, which may not succeed.

The company also faces significant regulatory and reimbursement hurdles for a novel diagnostic, and must overcome physician adoption challenges in a traditionally slow-to-change field.

Competitive Landscape

The field of precision respiratory diagnostics is emerging but fragmented. Competition includes large diagnostic companies (e.g., Roche, Thermo Fisher) with broad omics capabilities, startups focusing on breath analysis or other biomarkers, and pharmaceutical companies developing companion diagnostics for their own drugs. Diag-Nose.io's focus on nasal proteomics and the unified airway is a differentiating approach.

More companies in Diagnostics & Precision Medicine →More companies in United States →